Outcomes Following Salvage Radiation and Systemic Therapy for Isolated Locoregional Recurrence of Breast Cancer after Mastectomy: Impact of Constructed Biologic Subtype

Table 1

Patient characteristics at time of primary diagnosis and initial treatment (n=269).

Parameters		Value
Median age (range) (years)		47 (26-83)
Menopausal status
	Pre-/peri	162 (60.2%)
	Post-	107 (39.8%)
Location of primary tumor
	Medial	90 (33.5%)
	Central	21 (7.8%)
	Outer	158 (58.7%)
Primary tumor histopathology
	IDC	254 (94.4%)
	Others	15 (5.6%)
Primary tumor stage
	pT1	87 (32.3%)
	pT2	157 (58.4%)
	pT3	25 (9.3%)
No. of nodes removed		13 (5-31)
Nodal stages
	pN0	144 (53.5%)
	pN1	125 (46.5%)
Biologic subtype
	Rec+/HER2-	158 (58.7%)
	Rec+/HER2+	26 (9.7%)
	Rec-/HER2+	24 (8.9%)
	Rec-/HER2-	61 (22.7%)
Primary surgery
	MRM	228 (84.8%)
	Others	41 (15.2%)
Initial systemic therapy
	Chemotherapy only	104 (38.7%)
	Endocrine therapy only	11 (4.1%)
	Chemotherapy + endocrine therapy	147 (54.6%)
	Anti-HER2	4 (1.5%)
	None	7 (2.6%)

IDC = invasive ductal carcinoma; Rec = hormonal receptor; HER2 = human epidermal growth factor receptor 2; MRM = modified radical mastectomy.